Pancreatic Cancer Research

ResearcherNagoya University HospitalActive in the last 2 years

Yukihiro Yokoyama

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2385-5610; OpenAlex author ID A5052829488. Sources: OpenAlex.

Their work

Papers
26 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
77
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper · 2026: 4 papers

Papers 26

  1. Clinical Outcomes of Gemcitabine Plus Nab-Paclitaxel-Based Chemoradiotherapy in a Multidisciplinary Treatment Strategy for Locally Advanced Pancreatic Cancer (… Co-author DOI 10.1002/ijc.70801↗
  2. Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Control… Co-author DOI 10.1002/jhbp.70150↗
  3. High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-025-18912-3↗
  4. ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-026-19134-x↗
  5. Close correlation between patients' positive mood and postoperative complication burden in hepato-biliary-pancreatic cancer: a prospective comparative cohort t… First author DOI 10.1016/j.hpb.2025.07.015↗
  6. Trefoil factor 1 suppresses stemness and enhances chemosensitivity of pancreatic cancer. Co-author DOI 10.1002/cam4.7395↗
  7. Impact of sarcopenia on biliary drainage during neoadjuvant therapy for pancreatic cancer. Co-author DOI 10.5946/ce.2022.278↗
  8. Impact of skeletal muscle mass on the prognosis of patients undergoing neoadjuvant chemotherapy for resectable or borderline resectable pancreatic cancer. Co-author DOI 10.1007/s10147-023-02321-1↗
  9. Antitumor Effects of Deep Ultraviolet Irradiation for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16198↗
  10. Cyclodextrin Conjugated α-Bisabolol Suppresses FAK Phosphorylation and Induces Apoptosis in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16245↗
  11. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). First author DOI 10.1097/sla.0000000000005430↗
  12. Tumor marker recovery rather than major pathological response is a preferable prognostic factor in patients with pancreatic ductal adenocarcinoma with preopera… First author DOI 10.1002/jhbp.748↗
  13. FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection: A Secondary Analysis of the Nationwide Multicenter Observational Study Conducted by the … Co-author DOI 10.1097/mpa.0000000000001692↗
  14. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 … Co-author DOI 10.18999/nagjms.81.2.233↗
  15. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1007/s00280-018-3554-3↗
  16. Trefoil factor family 1 expression in the invasion front is a poor prognostic factor associated with lymph node metastasis in pancreatic cancer. Co-author DOI 10.1016/j.pan.2017.07.188↗
  17. The Anticancer Effects of Novel α-Bisabolol Derivatives Against Pancreatic Cancer. Co-author DOI 10.21873/anticanres.11352↗
  18. Nek2 siRNA therapy using a portal venous port-catheter system for liver metastasis in pancreatic cancer. Co-author DOI 10.1111/cas.12993↗
  19. α-Bisabolol Inhibits Invasiveness and Motility in Pancreatic Cancer Through KISS1R Activation. Co-author PMID 26851012↗
  20. Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer. Co-author DOI 10.1002/cam4.453↗
  21. EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsis. Co-author DOI 10.1093/jjco/hyu127↗
  22. Quantitative proteomic profiling identifies DPYSL3 as pancreatic ductal adenocarcinoma-associated molecule that regulates cell adhesion and migration by stabil… Co-author DOI 10.1371/journal.pone.0079654↗
  23. Seven-signal proteomic signature for detection of operable pancreatic ductal adenocarcinoma and their discrimination from autoimmune pancreatitis. Co-author DOI 10.1155/2012/510397↗
  24. [Borderline resectable pancreatic cancer - a definition and effective treatment strategy]. Co-author PMID 22421757↗
  25. Role of extended surgery for pancreatic cancer: critical review of the four major RCTs comparing standard and extended surgery. Co-author DOI 10.1007/s00534-011-0432-3↗
  26. Antitumor effects of α-bisabolol against pancreatic cancer. Co-author DOI 10.1111/j.1349-7006.2011.02082.x↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junpei Yamaguchi · 17 shared papers, 2015–2026 · strength 2.66
  2. Tomoki Ebata · 11 shared papers, 2012–2026 · strength 1.86
  3. Shunsuke Onoe · 6 shared papers, 2020–2025 · strength 1.02
  4. Hiroki Kawashima · 6 shared papers, 2018–2026 · strength 0.97
  5. Osamu Maeda · 6 shared papers, 2018–2026 · strength 0.97
  6. Toshio Kokuryo · 10 shared papers, 2011–2024 · strength 0.92
  7. Masamichi Hayashi · 6 shared papers, 2018–2026 · strength 0.91
  8. Masaki Sunagawa · 5 shared papers, 2017–2025 · strength 0.82
  9. Yasuhiro Kodera · 6 shared papers, 2018–2024 · strength 0.74
  10. Takuya Ishikawa · 4 shared papers, 2019–2026 · strength 0.69
  11. Mitsuro Kanda · 3 shared papers, 2026 · strength 0.67
  12. Nobuhiko Nakagawa · 3 shared papers, 2026 · strength 0.67
  13. Suguru Yamada · 5 shared papers, 2018–2026 · strength 0.67
  14. Tsutomu Fujii · 5 shared papers, 2018–2026 · strength 0.60
  15. Nobumasa Mizuno · 4 shared papers, 2012–2026 · strength 0.50
  16. Katsuhiko Uesaka · 3 shared papers, 2014–2026 · strength 0.48
  17. Tomohisa Otsu · 2 shared papers, 2026 · strength 0.45
  18. Shinji Mii · 2 shared papers, 2026 · strength 0.45
  19. Ryo Ashida · 2 shared papers, 2026 · strength 0.45
  20. Motokazu Sugimoto · 2 shared papers, 2026 · strength 0.45
  21. Hirochika Toyama · 2 shared papers, 2026 · strength 0.45
  22. Atsuyuki Maeda · 2 shared papers, 2026 · strength 0.45
  23. Keizo Fujita · 2 shared papers, 2026 · strength 0.45
  24. Eizaburo Ohno · 3 shared papers, 2019–2024 · strength 0.40
  25. Masato Nagino · 5 shared papers, 2012–2022 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.